Biologically Active Small Molecules

A non-sedating ophthalmic antihistamine that antagonizes histamine H1 receptors (IC₅₀ = 1.58 nM) and prevents the release of pro-inflammatory mediators from mast cells and eosinophils.

A non-sedating ophthalmic antihistamine that antagonizes histamine H1 receptors (IC₅₀ = 1.58 nM) and prevents the release of pro-inflammatory mediators from mast cells and eosinophils.

A non-sedating ophthalmic antihistamine that antagonizes histamine H1 receptors (IC₅₀ = 1.58 nM) and prevents the release of pro-inflammatory mediators from mast cells and eosinophils.

A stereoisomer of the antitumor anthracycline doxorubicin that undergoes &beta-glucuronidation, which partially detoxifies the dose-limiting side effects that are present with doxorubicin equally cytotoxic to HeLa cells compared to doxorubicin

A stereoisomer of the antitumor anthracycline doxorubicin that undergoes &beta-glucuronidation, which partially detoxifies the dose-limiting side effects that are present with doxorubicin equally cytotoxic to HeLa cells compared to doxorubicin

A stereoisomer of the antitumor anthracycline doxorubicin that undergoes &beta-glucuronidation, which partially detoxifies the dose-limiting side effects that are present with doxorubicin equally cytotoxic to HeLa cells compared to doxorubicin

A stereoisomer of the antitumor anthracycline doxorubicin that undergoes &beta-glucuronidation, which partially detoxifies the dose-limiting side effects that are present with doxorubicin equally cytotoxic to HeLa cells compared to doxorubicin

A potassium-sparing diuretic that selectively blocks aldosterone activation of the mineralcorticoid receptor (IC₅₀ = 122 nM) indicated for the treatment of hypertension and heart failure.

A potassium-sparing diuretic that selectively blocks aldosterone activation of the mineralcorticoid receptor (IC₅₀ = 122 nM) indicated for the treatment of hypertension and heart failure.

A potassium-sparing diuretic that selectively blocks aldosterone activation of the mineralcorticoid receptor (IC₅₀ = 122 nM) indicated for the treatment of hypertension and heart failure.

A potassium-sparing diuretic that selectively blocks aldosterone activation of the mineralcorticoid receptor (IC₅₀ = 122 nM) indicated for the treatment of hypertension and heart failure.

An antimicrotubule agent that binds to &beta-tubulin with a similar order of magnitude as the binding of paclitaxel to &beta-tubulin (IC₅₀s = 2.3 and 3.